Essayer OR - Gratuit

API China focuses on innovation & global co-operation

Chronicle Pharmabiz

|

October 30, 2025

In recent years, the scale of China's pharmaceutical active pharmaceutical ingredients (APIs) and its global market share have gradually increased. The China API market is experiencing significant growth, driven by expanding global pharmaceutical demand, an aging population, rising chronic disease rates, and the expiration of patents boosting demand for generics.

- Our Bureau, Mumbai

API China focuses on innovation & global co-operation

China stands as a colossus in the APIs landscape, accounting for approximately 40 per cent of the global market share, particularly dominating sectors like antibiotics and vitamins.

Even as leading domestic companies, such as Suzhou Biopharmaceuticals and BGI, are expanding market share through technological advancements, global giants like Pfizer and Novartis consolidate their positions via partnerships or acquisitions. Biotech firms are also emerging in the bio-API sector through innovative R&D.

The Chinese government is actively implementing initiatives to boost the API sector. Key policies encourage industry consolidation and strict regulatory compliance, fostering a more efficient and competitive market environment. The government is promoting centralized procurement to drive down costs and enhance efficiency, which also incentivizes enterprises to invest more in R&D to remain competitive.

API China expo

Even as the country's API sector is now undergoing a significant transformation marked by technological innovation, supply chain integration, and global expansion, the 93rd edition of API China which is being held from November 12 to 14 2025, in Chongqing, offers a renewed platform for industry players to stay ahead of evolving trends, explore new opportunities, and shape the future of pharmaceutical and health innovation.

API China, the country's leading exhibition for the pharmaceutical and biopharmaceutical industries, serves as a trusted platform for sourcing, innovation, and partnership. It brings together the full spectrum of the pharma, health, and nutrition ecosystem—from APIs, intermediates, and excipients to formulations, packaging, manufacturing equipment, CDMO services, and biotech solutions.

Organised by Reed Sinopharm Exhibitions, API China connects global professionals with China's dynamic life sciences market through high-level exhibitions, forums, and strategic exchange.

PLUS D'HISTOIRES DE Chronicle Pharmabiz

Chronicle Pharmabiz

Recent developments in Bangladesh pharma industry

Over the past four decades, the pharmaceutical industry in Bangladesh has undergone a sweeping transformation- emerging from its modest, import-dependent roots into a powerful, innovation-driven sector at the forefront of national development. What once relied heavily on foreign suppliers for basic medicines has now evolved into a self-reliant, technologically advanced industry capable of producing everything from lifesaving generics to complex oncology drugs.

time to read

7 mins

October 30, 2025

Chronicle Pharmabiz

Asia Labex showcases latest advancements in lab technology

DRIVEN by increased investment in pharmaceutical and biotech R&D, a rising need for advanced diagnostic equipment due to disease prevalence, and the growing adoption of automation in labs, the pharma laboratory equipment market has positive prospects.

time to read

6 mins

October 30, 2025

Chronicle Pharmabiz

AMMOI demands insurance for Ayurveda day care therapies

THE Ayurvedic Medicine Manufacturers Organ- isation of India (AM- MOI) has sought Union Ayush Minister Prataprao Jadhav's immediate interven- tion to ensure health insurance covers for Ayurvedic day care therapies.

time to read

2 mins

October 30, 2025

Chronicle Pharmabiz

Global API market poised for significant changes

The global API market is poised for significant transformation in the coming decade, with growth concentrated in complex APIs, biologics, peptides, and high-potency APIS (HPAPIs).

time to read

6 mins

October 30, 2025

Chronicle Pharmabiz

PvPI identifies 16 India specific signals

THE Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC) has identified 16 India specific signals. The same has been communicated to the Central Drugs Standard Control Organisation (CDSCO) for timely regulatory interventions towards patient safety.

time to read

2 mins

October 30, 2025

Chronicle Pharmabiz

CDSCO sets up digital system to monitor quality of solvents

THE Central Drugs Standard Control Organisation (CDSCO) has set up a Digital Monitoring System on the Online National Drugs Licensing System (ONDLS) portal to monitor the supply chain as well as quality of the high-risk solvents and has asked the State drug controllers to direct all manufacturers of pharma grade solvents to obtain manufacturing license through the portal.

time to read

2 mins

October 30, 2025

Chronicle Pharmabiz

Surgicals import grows 11.58%, exports remain stagnant in August

IMPORTS of surgical equipment to the country have reported a decline of 11.58% even as the export of these products was almost stagnant during the month of August, 2025. For the first five months of the current fiscal, imports registered almost 9% growth compared to the same period a year ago.

time to read

2 mins

October 30, 2025

Chronicle Pharmabiz

Chronicle Pharmabiz

API China focuses on innovation & global co-operation

In recent years, the scale of China's pharmaceutical active pharmaceutical ingredients (APIs) and its global market share have gradually increased. The China API market is experiencing significant growth, driven by expanding global pharmaceutical demand, an aging population, rising chronic disease rates, and the expiration of patents boosting demand for generics.

time to read

6 mins

October 30, 2025

Chronicle Pharmabiz

PVPI identifies 16 India specific signals

THE Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC) has identified 16 India specific signals. The same has been com- municated to the Central Drugs Standard Control Organisation (CDSCO) for timely regulatory interventions towards patient safety.

time to read

2 mins

October 30, 2025

Chronicle Pharmabiz

PM&AC 2025 redefines excellence in pharma manufacturing

THE 7th Annual Pharma Manufacturing & Automation Convention (PM&AC) 2025, co-located with the Pharma Manufacturing & Automation Excellence Awards, concluded on October 8 and 9 at Novotel HICC, Hyderabad, with resounding success.

time to read

3 mins

October 30, 2025

Listen

Translate

Share

-
+

Change font size